Compounded products and certification eligibility

The question arrives in the wrong form. Operators ask whether compounded products can be certified, as though eligibility were the issue. They can, routinely, and plenty of certified merchants sell them. The real question is whether your business can describe what it sells accurately enough to survive the review that comes with the category.

Why the category is scrutinised

A compounded preparation is not an approved drug. It has not been reviewed by the FDA for safety, effectiveness or quality. It exists because a prescriber determined that an individual patient needed something the approved market does not supply in that form.

That is a legitimate and long-standing part of medicine. It becomes a problem when a compounded preparation is marketed as though it were the approved product it resembles, at scale, to consumers who cannot tell the difference.

The scale of the resulting enforcement is documented. Our index of FDA warning letters covering compounded GLP-1 marketing lists every one of them, grouped into the enforcement rounds they were issued in and coded by what each letter cites: misbranding throughout, alongside approval claims, comparisons to the brand-name product and promises of safety or effectiveness.

A certification reviewer reading a compounded product page is reading for the same language.

The eligibility questions that actually decide it

Is there a genuine prescription behind each preparation? A compounded product supplied without an individual prescribing decision is not a marketing problem, it is the model the certification exists to screen out.

Can the compounder be identified and verified? Entity, registration type, state licensure, permitted scope. The difference between a traditional compounding pharmacy and an outsourcing facility is not cosmetic and stating it wrong is a discrepancy in your own file.

Is the preparation within what your partner may lawfully make? Including the ingredients, the format and the strength.

Does your website describe it as what it is? Compounded, not approved, not equivalent to the brand-name product, without borrowed trial results and without implied outcomes.

The first three are structural. The fourth is presentational, and it is where almost all of the failures are.

What "described accurately" means in practice

It means the word compounded appears where a patient will see it, not only in the terms of service. It means the pharmacy is named. It means no sentence attaches approval language to the preparation, including formulations engineered to be read as approval without stating it.

It means comparison is handled carefully. Comparative pricing framed against a named brand-name drug carries an equivalence implication whether or not the text states one, and equivalence is a claim nobody has evidence for.

It means personalisation is described honestly. Where the individualisation is a prescriber selecting among standard strengths, describing it as a bespoke formulation makes a claim about the product rather than about the service.

The full working version of this is in marketing compounded products without a misbranding problem, and it applies as squarely to men's health combination products as it does to weight management, which the men's health article covers.

Categories that carry extra weight

Not exhaustive, but these attract the closest reading: weight management involving compounded GLP-1 receptor agonists, hormone therapy including testosterone and menopause products, peptides, and combination products in men's health.

The common factor is a compounded preparation with an approved analogue that patients recognise, which is exactly the situation where a comparison is tempting and where it is most damaging.

What supply status does not change

Availability of an approved product moves over time, and the rules that apply to compounding move with it. What does not move is the marketing standard: whatever the supply position, a compounded preparation is not an approved product and may not be presented as one.

Brands that built copy around a particular supply situation should assume that copy has a shelf life and should not assume the compliance position moves with the market. Re-auditing the claims when the underlying circumstances change is part of maintaining certification rather than part of obtaining it.

What to do before you apply

Establish the three structural facts, prescription, compounder, scope, and write them down. Then run the claims audit, because that is the long pole and it is what disqualifies applications in this category.

If you are new to the certification itself, what it actually is is the better starting point, because the eligibility question is easier to answer once it is clear what is being certified.

Three questions that settle eligibility quickly

Ask these before spending time on anything else, because a no to any of them is a conversation about the model rather than about the file.

Does a licensed prescriber make an individual decision for every preparation dispensed? If the honest answer is that the decision is effectively automatic, the problem is structural and no amount of preparation reaches it.

Can you name the compounder and evidence its registration and scope? If the dispensing entity behind your fulfilment arrangement cannot be established, you have a gap you cannot close from your side.

Could every claim on your site survive being read by somebody who is looking for the four sentences? If not, the work is presentational and it is entirely doable, but it is work and it comes before filing rather than after.

What to expect from the review itself

Expect questions, and expect them to be about the claims rather than about the clinical model, because the claims are what a reviewer can see without asking. Expect the pharmacy documentation to be requested if it was not supplied.

And expect the review to look at pages you had forgotten: the old landing page variant still receiving traffic, the email sequence written by somebody who has left, the affiliate creative you never approved. Those are the three places the sentence you removed from the product page usually still lives, and they are cheap to sweep before submission and expensive to discover during a review.